Veronica Ghiglieri

List of Publications by Year
in descending order

#	Article	IF	Citations
1	Direct and indirect pathways of basal ganglia: a critical reappraisal. Nature Neuroscience, 2014, 17, 1022-1030.	14.8	598
2	Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap. Lancet Neurology, The, 2010, 9, 1106-1117.	10.2	329
3	A Critical Interaction between NR2B and MAGUK in L-DOPA Induced Dyskinesia. Journal of Neuroscience, 2006, 26, 2914-2922.	3.6	243
4	Prenatal exposure to a cannabinoid agonist produces memory deficits linked to dysfunction in hippocampal long-term potentiation and glutamate release. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 4915-4920.	7.1	176
5	Distinct Levels of Dopamine Denervation Differentially Alter Striatal Synaptic Plasticity and NMDA Receptor Subunit Composition. Journal of Neuroscience, 2010, 30, 14182-14193.	3.6	155
6	Effects of central and peripheral inflammation on hippocampal synaptic plasticity. Neurobiology of Disease, 2013, 52, 229-236.	4.4	155
7	The Distinct Role of Medium Spiny Neurons and Cholinergic Interneurons in the D₂/A_{2A}Receptor Interaction in the Striatum: Implications for Parkinson's Disease. Journal of Neuroscience, 2011, 31, 1850-1862.	3.6	140
8	Alpha-Synuclein: From Early Synaptic Dysfunction to Neurodegeneration. Frontiers in Neurology, 2018, 9, 295.	2.4	138
9	Blunting neuroinflammation with resolvin D1 prevents early pathology in a rat model of Parkinsonâ€™s disease. Nature Communications, 2019, 10, 3945.	12.8	127
10	Inhibition of phosphodiesterases rescues striatal long-term depression and reduces levodopa-induced dyskinesia. Brain, 2011, 134, 375-387.	7.6	125
11	Mechanisms underlying the impairment of hippocampal long-term potentiation and memory in experimental Parkinsonâ€™s disease. Brain, 2012, 135, 1884-1899.	7.6	124
12	Short-term and long-term plasticity at corticostriatal synapses: Implications for learning and memory. Behavioural Brain Research, 2009, 199, 108-118.	2.2	115
13	l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation. Neurobiology of Disease, 2008, 29, 327-335.	4.4	105
14	Molecular mechanisms underlying levodopa-induced dyskinesia. Movement Disorders, 2008, 23, S570-S579.	3.9	99
15	Hyperkinetic disorders and loss of synaptic downscaling. Nature Neuroscience, 2016, 19, 868-875.	14.8	98
16	Synaptic dysfunction in Parkinson's disease. Biochemical Society Transactions, 2010, 38, 493-497.	3.4	96
17	Dopamine-Dependent Long-Term Depression Is Expressed in Striatal Spiny Neurons of Both Direct and Indirect Pathways: Implications for Parkinson's Disease. Journal of Neuroscience, 2011, 31, 12513-12522.	3.6	94
18	Alpha-synuclein targets GluN2A NMDA receptor subunit causing striatal synaptic dysfunction and visuospatial memory alteration. Brain, 2019, 142, 1365-1385.	7.6	82

#	Article	IF	Citations
19	Plastic and behavioral abnormalities in experimental Huntington's disease: A crucial role for cholinergic interneurons. Neurobiology of Disease, 2006, 22, 143-152.	4.4	79
20	Alpha-Synuclein Produces Early Behavioral Alterations via Striatal Cholinergic Synaptic Dysfunction by Interacting With GluN2D N -Methyl-D-Aspartate Receptor Subunit. Biological Psychiatry, 2016, 79, 402-414.	1.3	77
21	Levodopa-induced plasticity: a double-edged sword in Parkinson's disease?. Philosophical Transactions of the Royal Society B: Biological Sciences, 2015, 370, 20140184.	4.0	71
22	Hippocampal Synaptic Plasticity, Memory, and Epilepsy: Effects of Long-Term Valproic Acid Treatment. Biological Psychiatry, 2010, 67, 567-574.	1.3	68
23	Persistent activation of microglia and NADPH oxidase drive hippocampal dysfunction in experimental multiple sclerosis. Scientific Reports, 2016, 6, 20926.	3.3	68
24	Rebalance of Striatal NMDA/AMPA Receptor Ratio Underlies the Reduced Emergence of Dyskinesia During D2-Like Dopamine Agonist Treatment in Experimental Parkinson's Disease. Journal of Neuroscience, 2012, 32, 17921-17931.	3.6	67
25	Derangement of Ras-Guanine Nucleotide-Releasing Factor 1 (Ras-GRF1) and Extracellular Signal-Regulated Kinase (ERK) Dependent Striatal Plasticity in L-DOPA-Induced Dyskinesia. Biological Psychiatry, 2015, 77, 106-115.	1.3	67
26	Repetitive transcranial magnetic stimulation reduces remote apoptotic cell death and inflammation after focal brain injury. Journal of Neuroinflammation, 2016, 13, 150.	7.2	62
27	Motor learning and metaplasticity in striatal neurons: relevance for Parkinsonâ€™s disease. Brain, 2018, 141, 505-520.	7.6	62
28	Neuronal networks and synaptic plasticity in Parkinson's disease: beyond motor deficits. Parkinsonism and Related Disorders, 2007, 13, S259-S262.	2.2	55
29	Modulation of serotonergic transmission by eltoprazine in L-DOPA-induced dyskinesia: Behavioral, molecular, and synaptic mechanisms. Neurobiology of Disease, 2016, 86, 140-153.	4.4	53
30	The Endocannabinoid System in Parkinsons Disease. Current Pharmaceutical Design, 2008, 14, 2337-2346.	1.9	52
31	Dopamine-dependent early synaptic and motor dysfunctions induced by Î±-synuclein in the nigrostriatal circuit. Brain, 2021, 144, 3477-3491.	7.6	49
32	Striatumâ€“hippocampus balance: From physiological behavior to interneuronal pathology. Progress in Neurobiology, 2011, 94, 102-114.	5.7	43
33	Assemblies of glutamate receptor subunits with post-synaptic density proteins and their alterations in Parkinsonâ€™s disease. Progress in Brain Research, 2010, 183, 169-182.	1.4	41
34	Rabphilin 3A: A novel target for the treatment of levodopa-induced dyskinesias. Neurobiology of Disease, 2017, 108, 54-64.	4.4	40
35	Rhes influences striatal cAMP/PKA-dependent signaling and synaptic plasticity in a gender-sensitive fashion. Scientific Reports, 2015, 5, 10933.	3.3	38
36	Intermittent thetaâ€burst stimulation rescues dopamineâ€dependent corticostriatal synaptic plasticity and motor behavior in experimental parkinsonism: Possible role of glial activity. Movement Disorders, 2017, 32, 1035-1046.	3.9	38

#	Article	IF	Citations
37	Electrophysiological and pharmacological characteristics of nigral dopaminergic neurons in the conscious, head-restrained rat. Synapse, 2003, 48, 1-9.	1.2	33
38	TrkB/BDNF-Dependent Striatal Plasticity and Behavior in a Genetic Model of Epilepsy: Modulation by Valproic Acid. Neuropsychopharmacology, 2010, 35, 1531-1540.	5.4	32
39	Plastic abnormalities in experimental Huntington's disease. Current Opinion in Pharmacology, 2007, 7, 106-111.	3.5	30
40	Region- and age-dependent reductions of hippocampal long-term potentiation and NMDA to AMPA ratio in a genetic model of Alzheimer's disease. Neurobiology of Aging, 2015, 36, 123-133.	3.1	30
41	Impaired Plasticity at Specific Subset of Striatal Synapses in the Ts65Dn Mouse Model of Down Syndrome. Biological Psychiatry, 2010, 67, 666-671.	1.3	28
42	Epilepsyâ€induced abnormal striatal plasticity in Bassoon mutant mice. European Journal of Neuroscience, 2009, 29, 1979-1993.	2.6	26
43	Striatal glutamatergic hyperactivity in Parkinson's disease. Neurobiology of Disease, 2022, 168, 105697.	4.4	26
44	Acetyl-l-Carnitine selectively prevents post-ischemic LTP via a possible action on mitochondrial energy metabolism. Neuropharmacology, 2008, 55, 223-229.	4.1	25
45	Environmental enrichment restores CA1 hippocampal LTP and reduces severity of seizures in epileptic mice. Experimental Neurology, 2014, 261, 320-327.	4.1	25
46	Rhes regulates dopamine D2 receptor transmission in striatal cholinergic interneurons. Neurobiology of Disease, 2015, 78, 146-161.	4.4	25
47	NMDA receptor GluN2D subunit participates to levodopa-induced dyskinesia pathophysiology. Neurobiology of Disease, 2019, 121, 338-349.	4.4	24
48	mTOR inhibitor rapamycin suppresses striatal post-ischemic LTP. Experimental Neurology, 2010, 226, 328-331.	4.1	23
49	Hippocampal enlargement in Bassoon-mutant mice is associated with enhanced neurogenesis, reduced apoptosis, and abnormal BDNF levels. Cell and Tissue Research, 2011, 346, 11-26.	2.9	23
50	Theta-burst stimulation and striatal plasticity in experimental parkinsonism. Experimental Neurology, 2012, 236, 395-398.	4.1	23
51	Neurofunctional Effects of Developmental Alcohol Exposure in Alcohol-Preferring and Alcohol-Nonpreferring Rats. Neuropsychopharmacology, 2001, 24, 691-705.	5.4	22
52	Hippocampal neuroplasticity and inflammation: relevance for multiple sclerosis. Multiple Sclerosis and Demyelinating Disorders, 2017, 2, .	1.1	19
53	Cigarette smoke inhalation stimulates dopaminergic neurons in rats. NeuroReport, 2000, 11, 3637-3639.	1.2	18
54	Interaction between basal ganglia and limbic circuits in learning and memory processes. Parkinsonism and Related Disorders, 2016, 22, S65-S68.	2.2	18

#	Article	IF	Citations
55	Rapamycin, by Inhibiting mTORC1 Signaling, Prevents the Loss of Striatal Bidirectional Synaptic Plasticity in a Rat Model of L-DOPA-Induced Dyskinesia. Frontiers in Aging Neuroscience, 2020, 12, 230.	3.4	18
56	Functional interactions within striatal microcircuit in animal models of Huntington's disease. Neuroscience, 2012, 211, 165-184.	2.3	17
57	Interferon-Î²1a protects neurons against mitochondrial toxicity via modulation of STAT1 signaling: Electrophysiological evidence. Neurobiology of Disease, 2014, 62, 387-393.	4.4	17
58	Memantine alters striatal plasticity inducing a shift of synaptic responses toward long-term depression. Neuropharmacology, 2016, 101, 341-350.	4.1	16
59	Neuro-Immune Cross-Talk in the Striatum: From Basal Ganglia Physiology to Circuit Dysfunction. Frontiers in Immunology, 2021, 12, 644294.	4.8	16
60	Corticostriatal Plastic Changes in Experimental L-DOPA-Induced Dyskinesia. Parkinson's Disease, 2012, 2012, 1-10.	1.1	15
61	Striatal synaptic changes in experimental parkinsonism: Role of NMDA receptor trafficking in PSD. Parkinsonism and Related Disorders, 2008, 14, S145-S149.	2.2	14
62	Dopamine drives bingeâ€like consumption of a palatable food in experimental Parkinsonism. Movement Disorders, 2019, 34, 821-831.	3.9	11
63	Lâ€3,4â€dihydroxyphenylalanineâ€induced sprouting of serotonin axon terminals: A useful biomarker for dyskinesias?. Annals of Neurology, 2010, 68, 578-580.	5.3	10
64	Corticostriatal synaptic plasticity alterations in the R6/1 transgenic mouse model of Huntington's disease. Journal of Neuroscience Research, 2019, 97, 1655-1664.	2.9	10
65	Transcranial Magnetic Stimulation Exerts â€œRejuvenationâ€• Effects on Corticostriatal Synapses after Partial Dopamine Depletion. Movement Disorders, 2021, 36, 2254-2263.	3.9	10
66	l-DOPA reverses the impairment of Dentate Gyrus LTD in experimental parkinsonism via Î²-adrenergic receptors. Experimental Neurology, 2014, 261, 377-385.	4.1	9
67	Effects of safinamide on the glutamatergic striatal network in experimental Parkinsonâ€™s disease. Neuropharmacology, 2020, 170, 108024.	4.1	8
68	CalDAG-GEFI mediates striatal cholinergic modulation of dendritic excitability, synaptic plasticity and psychomotor behaviors. Neurobiology of Disease, 2021, 158, 105473.	4.4	8
69	Effects of uremic toxins on hippocampal synaptic transmission: implication for neurodegeneration in chronic kidney disease. Cell Death Discovery, 2021, 7, 295.	4.7	8
70	Attachment and parental reflective functioning features in ADHD: enhancing the knowledge on parenting characteristics. Frontiers in Psychology, 2015, 6, 1313.	2.1	6
71	Striatal spreading depolarization: Possible implication in levodopaâ€induced dyskineticâ€like behavior. Movement Disorders, 2019, 34, 832-844.	3.9	6
72	Direct and indirect pathways in levodopaâ€induced dyskinesia: A more complex matter than a network imbalance. Movement Disorders, 2010, 25, 1527-1529.	3.9	5

#	Article	IF	Citations
73	Prenatal stress and hippocampal BDNF expression: a fading imperative. Journal of Physiology, 2012, 590, 1309-1310.	2.9	4
74	Alpha-synuclein and cortico-striatal plasticity in animal models of Parkinson disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2022, 184, 153-166.	1.8	4
75	Maternal stress programs accelerated aging of the basal ganglia motor system in offspring. Neurobiology of Stress, 2020, 13, 100265.	4.0	3
76	Serotonin drives striatal synaptic plasticity in a sex-related manner. Neurobiology of Disease, 2021, 158, 105448.	4.4	3
77	Rhes, a key element of selective neuronal vulnerability in Huntington's disease: A striatalâ€specific license to kill during energy metabolism failure. Movement Disorders, 2013, 28, 735-735.	3.9	2
78	â€œLazyâ€• nigrostriatal synapses in the heterozygous PINK1 mouse model of familial Parkinson's disease. Movement Disorders, 2014, 29, 11-14.	3.9	2
79	Long-Term Shaping of Corticostriatal Synaptic Activity by Acute Fasting. International Journal of Molecular Sciences, 2021, 22, 1916.	4.1	2
80	Environmental Enrichment Repairs Structural and Functional Plasticity in the Hippocampus. , 2017, , 55-77.		1
81	Reply to: Rewiring Brains in Parkinson's Disease: The New Era of Brain Stimulation. Movement Disorders, 2021, 36, 2979-2980.	3.9	0